Ruth Dobson1, Richard A Rudick, Ben Turner, Klaus Schmierer, Gavin Giovannoni. 1. From the Queen Mary University London (R.D., K.S., G.G.), Blizard Institute, UK; Neurological Institute (R.A.R.), Mellen Center for MS Treatment and Research, Cleveland, OH; and Royal London Hospital (R.D., B.T., K.S., G.G.), Barts Health NHS Trust, UK.
Abstract
OBJECTIVE: Interferon-β (IFN-β) has been shown to reduce relapse rates in multiple sclerosis; however, the clinical response appears to vary among individuals. Can early MRI be used to identify those patients who have a poor response to treatment? METHODS: A systematic review of studies examining differential treatment response and clinical endpoints in groups defined as responders or nonresponders to IFN-β was performed. Meta-analytic techniques were used to combine study results where appropriate. RESULTS: Patients with MRI evidence of poor response to IFN-β treatment as defined by either ≥2 new hyperintense T2 lesions or new gadolinium-enhancing lesions had significantly increased risk of both future relapses and progression as defined by the Expanded Disability Status Scale. There appeared to be an increased risk of poor outcomes 16 years after treatment initiation in those with an initial poor response to treatment. Previous evidence has shown this not to be the case in placebo arms of clinical trials. CONCLUSIONS: For those patients starting IFN-β, early MRI, within 6 to 24 months after starting treatment, has the potential to provide important information when counseling patients about the likelihood of future treatment failure. This can inform treatment decisions before clinical relapses or disease progression.
OBJECTIVE: Interferon-β (IFN-β) has been shown to reduce relapse rates in multiple sclerosis; however, the clinical response appears to vary among individuals. Can early MRI be used to identify those patients who have a poor response to treatment? METHODS: A systematic review of studies examining differential treatment response and clinical endpoints in groups defined as responders or nonresponders to IFN-β was performed. Meta-analytic techniques were used to combine study results where appropriate. RESULTS:Patients with MRI evidence of poor response to IFN-β treatment as defined by either ≥2 new hyperintense T2 lesions or new gadolinium-enhancing lesions had significantly increased risk of both future relapses and progression as defined by the Expanded Disability Status Scale. There appeared to be an increased risk of poor outcomes 16 years after treatment initiation in those with an initial poor response to treatment. Previous evidence has shown this not to be the case in placebo arms of clinical trials. CONCLUSIONS: For those patients starting IFN-β, early MRI, within 6 to 24 months after starting treatment, has the potential to provide important information when counseling patients about the likelihood of future treatment failure. This can inform treatment decisions before clinical relapses or disease progression.
Authors: L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: Antonio Scalfari; Anneke Neuhaus; Martin Daumer; Paolo Antonio Muraro; George Cornell Ebers Journal: J Neurol Neurosurg Psychiatry Date: 2013-03-13 Impact factor: 10.154
Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422
Authors: Maria Pia Sormani; Paolo Bruzzi; Karola Beckmann; Ludwig Kappos; David H Miller; Chris Polman; Carlo Pozzilli; Alan J Thompson; Klaus Wagner; Massimo Filippi Journal: J Neurol Date: 2005-07-18 Impact factor: 4.849
Authors: S Galler; J-P Stellmann; K L Young; D Kutzner; C Heesen; J Fiehler; S Siemonsen Journal: AJNR Am J Neuroradiol Date: 2016-01-07 Impact factor: 3.825
Authors: Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven Journal: Nat Rev Neurol Date: 2017-01-13 Impact factor: 42.937
Authors: Thomas Lehnert; Christian Röver; Sascha Köpke; Jordi Rio; Declan Chard; Andrea V Fittipaldo; Tim Friede; Christoph Heesen; Anne C Rahn Journal: Syst Rev Date: 2022-07-01
Authors: S Mahurkar; M Moldovan; V Suppiah; M Sorosina; F Clarelli; G Liberatore; S Malhotra; X Montalban; A Antigüedad; M Krupa; V G Jokubaitis; F C McKay; P N Gatt; M J Fabis-Pedrini; V Martinelli; G Comi; J Lechner-Scott; A G Kermode; M Slee; B V Taylor; K Vandenbroeck; M Comabella; F M Boneschi; C King Journal: Pharmacogenomics J Date: 2016-03-22 Impact factor: 3.550
Authors: Hans-Peter Hartung; Ludwig Kappos; Douglas S Goodin; Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Jeffery; John Petkau; Richard White; Timon Bogumil; Karola Beckmann; Brigitte Stemper; Gustavo Suarez; Rupert Sandbrink; Christoph Pohl Journal: J Neurol Date: 2015-08-05 Impact factor: 4.849